From alternatives to adoption: What the latest NC3Rs report tells us about animal-free research
The NC3Rs has published a new impact report examining progress towards replacing animal-derived products and reagents in in vitro research.
The scale of the work is encouraging. Across ten funded projects, more than 200 non-animal-derived reagents and model components have been characterised, validated or optimised, with the potential to replace the use of thousands of animals each year. The programme has also attracted more than £970,000 in follow-on funding.
But perhaps the most important message for the industry is not simply that more animal-free alternatives are becoming available. It is that the evidence needed to support their adoption is growing.
The challenge is moving from availability to confidence
Animal-derived products including foetal bovine serum, antibodies and extracellular matrices remain widely used across biomedical research.
As the NC3Rs highlights, these materials can present scientific as well as ethical challenges. Undefined composition, batch-to-batch variability and limited standardisation can compromise experimental reproducibility.
Alternatives are increasingly available, but researchers understandably need evidence that they can perform reliably in their specific experimental systems before moving away from established workflows.
This makes comparative validation particularly important. Researchers need to know that non-animal reagents can perform at least comparably to established materials in relevant applications and, ideally, offer scientific advantages beyond removing animal-derived components.
For the industry, the conversation is therefore moving beyond whether alternatives exist and towards building the evidence and confidence required for their routine adoption.
PeptiMatrix™: putting that principle into practice
We were particularly pleased to see one of our own collaborations featured in the NC3Rs report.
Dr Mattéa Finelli at the University of Nottingham, working with PeptiMatrix, StrataStem Ltd and Dr Richard Elsworthy at the University of Birmingham, characterised a human 3D model of Alzheimer’s disease using iPSC-derived neurones and astrocytes cultured within a defined PeptiMatrix peptide hydrogel.
As the NC3Rs reports:
“The peptide hydrogel, originally developed through NC3Rs funding and now commercially available via PeptiMatrix, enabled more than a 95% reduction in animal-derived material use compared with standard Matrigel-based systems.”
Crucially, the report goes on to highlight the performance of the model when compared with established approaches:
“When benchmarked against current gold standard models, the system showed comparable cell survival and differentiation, alongside improved reproducibility across experiments.”
For us, this is a particularly encouraging result. Replacing Matrigel and substantially reducing the use of animal-derived materials is important, but doing so while maintaining cell survival and differentiation and improving reproducibility demonstrates the wider scientific value that a defined synthetic matrix can offer.
The resulting 3D model is also compatible with 96-well formats and automated imaging, supporting higher-throughput studies of Alzheimer’s disease mechanisms and therapeutic screening. The team has since secured more than £70,000 in follow-on funding to further characterise and extend the model.
From alternative to enabling technology
There is an important distinction between developing something that can simply replace an animal-derived material and developing a technology that can improve the experimental system itself.
Defined synthetic matrices remove a source of biological variability while providing researchers with greater control over the 3D cell culture microenvironment. The results highlighted by NC3Rs demonstrate how this can translate into practical benefits for researchers working with complex human cell models.
For PeptiMatrix, this is where we see the real opportunity. The aim is not simply to replace materials such as Matrigel like-for-like, but to help researchers build more defined, reproducible and scalable 3D cell culture systems.
Building the evidence for change
The NC3Rs report provides an encouraging picture of progress towards wider use of non-animal reagents, while also highlighting the importance of robust validation and benchmarking.
For new technologies to become routinely adopted, researchers need comparative data generated in relevant biological systems. Collaborations between technology developers, academic researchers and other industry partners are an important part of building that evidence base.
We are proud that PeptiMatrix and our collaborators are contributing to this work, and particularly pleased to see our peptide hydrogels successfully replacing Matrigel in a complex iPSC-derived neuronal model while also improving experimental reproducibility.
Looking to move beyond Matrigel?
If you’re exploring defined, animal-free matrices for 3D cell culture, get in touch to discuss how PeptiMatrix could support your research:
Comments